Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the sale of its portfolio company Corvidia Therapeutics to Novo Nordisk, for $2.1 billion, including an upfront payment of $725 million. Corvidia, an AstraZeneca spin-off, is a clinical-stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. Sofinnova Partners was Corvidia’s sole seed financial investor in 2015 and it has remained the largest shareholder throughout the company’s evolution.
Sofinnova Partners helped recruit Corvidia’s top management team members, including Sylvie Grégoire, a seasoned pharma executive and entrepreneur, in 2016, to chair the Board, and Marc de Garidel as Chief Executive Officer in 2018. Before joining Corvidia, Mr. de Garidel was the Chairman and CEO of Ipsen, a publicly-listed French pharmaceutical company.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, commented, “This acquisition is the culmination of a quintessential Sofinnova Partners investment, from seed to exit. We are especially proud of the high-caliber team we helped establish, which includes veteran executives like Marc de Garidel, who has been instrumental in this deal.”
Mr. de Garidel, CEO of Corvidia, said, “Sofinnova Partners has played a central role in building this company from the very beginning, leveraging its extensive international network to bring in key hires and providing strategic guidance to advance our scientific work around precision therapies for cardiovascular diseases.”
Sofinnova Partners co-founded Corvidia alongside Michael Davidson, M.D., a serial entrepreneur and a recognized authority in the field of cardiology. Dr. Davidson was co-founder and Chief Medical Officer of Omthera Pharmaceuticals, for which Sofinnova Partners was also the lead investor, and which was acquired by AstraZeneca for $443 million in 2013.
Mr. Seghezzi added, “This milestone demonstrates the strength of our cornerstone strategy of backing extraordinary entrepreneurs with whom we have long-standing relationships. Moreover, it exemplifies the resilience of our business of developing game-changing therapies that will impact patients’ lives, while consistently generating outsized venture returns for investors, despite the challenges of the current global crisis.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
About Corvidia Therapeutics
Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company’s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia’s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit: www.corvidiatx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005512/en/
Contact information
Media Contacts:
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
Italy
Havas PR Milan
Marco Fusco
Marco.fusco@havaspr.com
+39 (0) 3456538145
Antonio Buozzi
antonio.buozzi@havaspr.com
+39 (0) 3200624418
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneyco.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frontgrade Gaisler Launches New GRAIN Line and Wins SNSA Contract to Commercialize First Energy-Efficient Neuromorphic AI for Space Applications2.4.2025 09:00:00 EEST | Press release
The Swedish National Space Agency (SNSA) has awarded Frontgrade Gaisler, a leading provider of radiation-hardened microprocessors for space missions, a contract to commercialize the first neuromorphic System on Chip (SoC) device for space applications. Already in development at Frontgrade Gaisler, the device is part of the company’s new GRAIN (Gaisler Research Artificial Intelligence NOEL-V) product line. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401194593/en/ Frontgrade Gaisler, a leading provider of radiation-hardened microprocessors for space missions, has launched its new Gaisler Research Artificial Intelligence NOEL-V (GRAIN) product line. The first GRAIN device to premiere – the Gr801 SoC – integrates Akida™ neuromorphic technology from BrainChip, the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI. The first GRAIN device that Frontgrade Gaisler will premiere –
Allshares Acquires Bolago to Strengthen Global Leadership and Expand Equity Management Offering2.4.2025 08:00:00 EEST | Press release
Allshares, a leading provider of equity and incentive management solutions, today announced the acquisition of Bolago, a company offering digital solutions for share programs, option schemes, and investments. The acquisition reinforces Allshares’ position as a leading global platform for end-to-end equity plan management and expands its capabilities in supporting growth-stage businesses and entrepreneurs. The deal follows Allshares’ recently announced accelerated growth strategy and builds on its global momentum. By integrating Bolago’s advanced technology for scenario planning and equity modeling, Allshares will broaden its product offering and further empower companies to manage incentive programs at scale. Hannes Rosén, CEO of Bolago, shared his excitement about the partnership: “Over the years, we’ve built a strong and diverse customer base and a talented team. Joining Allshares is a unique opportunity to elevate our service delivery with tech-forward compensation and equity softwa
Desentum Reports Strong Safety and Immunological Data From Phase 1 Clinical Study With Investigational Birch Pollen Allergy Vaccine DM-101PX2.4.2025 07:20:00 EEST | Press release
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch pollen allergic patients and to induce a very strong and sustained allergen-specific IgG4 response. DM-101PX-induced immunoglobulins were found to efficiently block IgE-mediated basophil activation endorsing the product’s potential to induce a protective immune response. The randomised, double-blind, placebo-controlled study evaluated three dose escalation regimens, each consisting of ten subcutaneous injections over 10 weeks with DM-101PX or placebo in a total of thirty birch pollen allergic adults. No serious or severe adverse events occurred, and most adverse events were local injection-site reactions that are typically seen in subcutaneous allergen immunotherapy. Nearly all patients reached their targeted maximum dose. T
GE HealthCare and FPT Expand Strategic Partnership to Drive AI-Powered Healthcare Innovation2.4.2025 07:06:00 EEST | Press release
Global IT firm FPT and GE HealthCare announced a Strategic Cooperation Agreement, expanding their commercial alliance to advance product strategy and development, and establish an FPT Competency Center in Vietnam. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401306987/en/ This deepening collaboration reflects a strategic shift from project-based engagement to a long-term alliance aimed at accelerating the adoption of AI-driven solutions, enhancing operational efficiency, and improving patient care. As part of the commercial alliance, FPT will become a channel partner for GE HealthCare, jointly promoting and delivering GE HealthCare’s digital solutions in Vietnam and throughout its country network. FPT also plans on collaborating with GE HealthCare’s Science & Technology Office and affiliates to co-develop new and further develop GE HealthCare’s existing and new digital healthcare products. A key highlight of the partner
Former Mitsubishi IP Leader to Head Sisvel Japan2.4.2025 07:00:00 EEST | Press release
Yoshinori Shimizu has become managing director of the Japanese office of Sisvel, Europe’s biggest and longest-established patent pool operator. The appointment coincides with the retirement of Tetsuro Fuse, who will continue to work with Sisvel in an advisory capacity. Mr Shimizu is widely acknowledged as one of Japan’s leading IP professionals and most recently served as Deputy General Manager of the Corporate Export Control Division at Mitsubishi Electric Corporation, where he worked for 29 years. During his time at Mitsubishi, Mr Shimizu was instrumental in shaping the company’s global IP strategy, negotiating patent licensing agreements and resolving disputes. He has also played a key role in several patent pool initiatives, including those operated by Sisvel. As managing director of Sisvel Japan, Mr Shimizu will work closely with Sisvel’s global leadership team to drive the continued growth of the firm’s licensing programmes in Japan and across Asia. “Having worked with Sisvel as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom